Resumen

ZEA QUISPE, Justiniano Oseas; ORIHUELA ECHAVIGURIN, Roberto Michael  y  LOPEZ GONZALES, Freddy Cristóbal. Nerve growth factor in traumatic optic neuropathy. Horiz. Med. [online]. 2023, vol.23, n.1, e2098.  Epub 03-Mar-2023. ISSN 1727-558X.  http://dx.doi.org/10.24265/horizmed.2023.v23n1.09.

Traumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objective of this study is to present the case of a patient who suffered from TON and, at the same time, an asymmetrical bilateral condition, and was treated with nerve growth factor (NGF). This drug was the first to be discovered and demonstrate efficacy in maintaining the survival of central and peripheral neurons and facilitating their growth, differentiation and regeneration. A 13-year-old male patient attended the emergency room of Instituto Nacional de Ciencias Neurológicas and was later followed up at the Neuro-Ophthalmology Service. He was diagnosed with post-traumatic amaurosis caused by traumatic brain injury and epidural hematoma, and received two treatment cycles of NGF. After the first treatment cycle, hyporeactivity of both eyes occurred. And, at the end of the second treatment cycle, visual acuity improved significantly. NGF has been approved and marketed in China since 2015 and is a product that has demonstrated its efficacy and safety in several clinical trials. Therefore, this study aims to make NGF a promising ITON treatment; in that sense, further clinical research is needed in this particular case.

Palabras clave : Nerve Growth Factor; Visual Acuity; Optic Nerve Diseases; Wounds and Injuries (Source: MeSH NLM)..

        · resumen en Español     · texto en Español     · Español ( pdf )